Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

• Forschungsstelle: INNOSUISSE
• Projektnummer: 15236.1 PFLS-LS
• Projekttitel Englisch: Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

Kurzbeschreibung (Deutsch)

Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

Kurzbeschreibung (Englisch)

Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

Abstract (Deutsch)

There is an increasing trend in the pharmaceutical industry to develop products based on new oral drug delivery technologies. This is mainly driven by the fact that delivery and establishment of a sufficient and controllable bioavailability of drugs are the major challenges of current oral dosage formulation developments. Innovative and new oral delivery techniques are not only of great interest for new products based on new chemical entities (NCE), but are also required to improve the efficacy of existing products.|In the context of these pharmaceutical challenges the proposed project aims at the development and validation of a patent protected pharmaceutical drug delivery formulation based on a new gastro-retentive technology platform. This granules based new gastro-retentive formulation technology will exhibit increased gastric retention, i.e. longer intra-gastric residence times, as compared to standard oral formulations. It is formed by the binding of active pharmaceutical ingredients (APIs) within a floating polymer matrix. The developed oral dosage technology will provide targeted and controlled delivery of therapeutic agents into the upper GI tract, the most effective site of absorption for many oral drug substances.|

Abstract (Englisch)

There is an increasing trend in the pharmaceutical industry to develop products based on new oral drug delivery technologies. This is mainly driven by the fact that delivery and establishment of a sufficient and controllable bioavailability of drugs are the major challenges of current oral dosage formulation developments. Innovative and new oral delivery techniques are not only of great interest for new products based on new chemical entities (NCE), but are also required to improve the efficacy of existing products.|In the context of these pharmaceutical challenges the proposed project aims at the development and validation of a patent protected pharmaceutical drug delivery formulation based on a new gastro-retentive technology platform. This granules based new gastro-retentive formulation technology will exhibit increased gastric retention, i.e. longer intra-gastric residence times, as compared to standard oral formulations. It is formed by the binding of active pharmaceutical ingredients (APIs) within a floating polymer matrix. The developed oral dosage technology will provide targeted and controlled delivery of therapeutic agents into the upper GI tract, the most effective site of absorption for many oral drug substances.|